OS Therapies Incorporated (OSTX) is a Healthcare · Biotechnology company listed on NYSE MKT. Price $1.80 (-1.64%), Market cap $0.08B, 52-week low–high $1.16 ~ $2.50.
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.
Financial statements, price targets, institutional (13F) holdings and related news for OS Therapies Incorporated are updated in real time on BlackAll Trade.
OS Therapies Incorporated trades at $1.80 (-1.64%). Real-time quotes and charts are available on BlackAll Trade.
OS Therapies Incorporated has a market cap of about $0.08B.
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the Un